Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 11
Submit an article Journal homepage
595
Views
132
CrossRef citations to date
0
Altmetric
Review

Pharmacotherapy for dyslipidaemia – current therapies and future agents

Harold Bays L-MARC Research Center, 3288 Illinois Avenue, Louisville KY 40213, USA. [email protected]
&
Evan A Stein L-MARC Research Center, 3288 Illinois Avenue, Louisville KY 40213, USA. [email protected]
Pages 1901-1938 | Published online: 02 Mar 2005

Bibliography

  • CANTOS JG, ISKANDRIAN AE: Majorrisk factors for cardiovascular disease — debunking the 'only 50% myth: JAMA (2003) 290(7):947–949.
  • BAYS HE: Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am. J. Cardiel1 (2002) 90(Suppl.):30K–43K.
  • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III). JA/VIA (2001) 285(19):2486–2497.
  • ••Latest recommendations of an expert paneltowards the treatment of dyslipidaemia.
  • SACKS FM, EXPERT GROUP ON HDL CHOLESTEROL: The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardiel (2002) 90:139–143.
  • •Latest recommendation of an expert panel towards the treatment of HDL-C.
  • BAYS HE: Ezetimibe. Expert Opin. Investig.Drugs (2002) 11(11):1587–1604
  • ••A comprehensive review of ezetimibe.
  • LAROSA JC: Pleiotropic effects of statinsand their clinical significance. Am. J. Cardiel. (2001) 88(3):291–293.
  • •Examines the real evidence behind the proposed benefits of statins beyond their lipid effects.
  • JONES PH, DAVIDSON MH, STEIN EA,BAYS HE et al: Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. I Cardiol (2003) 92:152-160.Direct comparison trial of rosuvastatin versus other statins.
  • SHEPHERD J, COBBE SM, FORD Iet al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West Of Scotland Coronary Prevention Study Group. N Engl. I Med. (1995) 333:1301–1307.
  • DOWNS JR, CLEARFIELD M, WETS Set al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. The Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615–1622.
  • SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149–1158.
  • SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol And Recurrent Events Trial Investigators. N Engl. Med. (1996) 335:1001–1009.
  • LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. Med. (1998) 19:1349–1357.
  • HEART Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
  • SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • STEIN EA, STRUTT K,SOUTHWORTH H et al: Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familialhyercholesterolemia. Am. Cardiol (In Press).
  • NEZASA K, TADAO A, KIMURA K, TAKAICHI M, INAZAWA K, KOIKE M: Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in rat. Xenobiotica (2002) 32(8):715–727.
  • AstraZeneca: Crestor® (rosuvastastin calcium) package insert. AstraZeneca Pharmaceuticals. Wilmington, DE 1919850, USA (2003).
  • Crestor® (ZD4522, rosuvastatin calcium) Tablets FDA Advisory Committee Meeting Briefing Document NDA 21–366 for the use of Crestor® June 11(2003).
  • DAVIDSON MH: Combination therapy for dyslipidemia: safety and regulatory considerations. Anti. Cardiol (2002) 90(Suppl.):50K–60K.
  • BREWER HB: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. Cardiol (2003) 92(Suppl.):23K–29K.
  • LIPID RESEARCH CLINICS PROGRAM: The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA (1984) 251:351–364.
  • BAYS HE, DUJOVNE CA: Colesevelam - a non-systemic lipid-altering drug. Expert Opin. Phannacother. (2003) 4(5):779–790.
  • •A comprehensive review of colesevelarn.
  • BAYS HE, MOORE PB, DREHOBL MA et al.: Ezetimibe Study Group effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Cilia. Titer. (2001) 23(8):1209–1230.
  • BAYS HE, VVEISS S, GAGNE C et al: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. Oral Contributions. Amer. Coll. Cardiol (2002) 39(5 Suppl. A):833-834 (245A).
  • GAGNE C, BAYS HE, VVEISS SR et al: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. The Ezetimibe Study Group. Am. I Cardiol (2002) 90:1084–1091.
  • ••A practical trial evaluating the use ofezetimibe added to a statin.
  • ZHU Y, STATKEVICH P, KOSOGLOU T et al: Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin. Pbarmacol Titer. (2000) 67:152 (Abstract).
  • CATAPANO AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Eur. Heart 1. (2001) 3 (Suppl. E):E6–E10.
  • VON BERGMANN K, SALEN G, LUTJOHANN D, MUSLINER T, MUSSER B: Ezetimibe effectively reduces serum plant sterols in patients with sitosterolemia. Atherosclerosis Stipp]. (2002) 3(2):232.
  • PLAT J, MENSINK RP: Effect of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. Fed. Am. Soc. Exp. Biol. (2002) 16(2):258–260.
  • MIETTINEN TA, GYLLING H: Regulation of cholesterol metabolism by dietary plant sterols. Carr: Opin. Lipidol (1999) 10:9–14.
  • MIETTINEN TA: Cholesterol absorption inhibition: a strategy for cholesterol lowering therapy. hat. Clin. Piaci (2001) 55(10):710–716.
  • RAEINI-SARJAZ M, NTANIOS FY, VANSTONE CA, JONES PJ: No changes in serum fat-soluble vitamin and carotenoid concentrations with the intake of plant sterol/stanol esters in the context of a controlled diet. Metabolism (2002) 51(5):652–656.
  • •Supports the fact that plant sterol/stanol esters do not adversely affect fat-soluble vitamins and carotenoids.
  • TAMMI A, RONNEMAA T, GYLLING H et al.: Plant stanol ester margarine lowers serum total and low-density lipoprotein cholesterol concentration of healthy children: The STRIP project. I Pediatr. (2000) 136(4):503–510.
  • ANDERSON RA: A holistic approach toprevention and health promotion: influences of physical activity, food supplements, and mind-body interactions on longevity and cardiac disease. Olin. Fain. Pract. (2002) 4(4):773.
  • •An optimistic view of how nutrients, physical activity, and lifestyle can improve health.
  • ANDERSSON M, ELLEGARD L, ANDERSSON H: Oat bran stimulates bile acid synthesis within 8 hours as measured 1931Expert Opin. Pharmacother. (2003) 4(11) ••by 7 alpha-hydroxy-4-cholesten-3-one.Am. J. Clin. Num. (2002) 76(5):1111–1116.
  • YU JNJ, CUNNINGHAM JA, THOUIN SR et al.: Hyperlipidemia. Prim. Care (2000) 27(3):541–587.
  • OLSON BH, ANDERSON SM, BECKER MP et al.: Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol in hypercholesterolemic adults: results of a meta-analysis. J. Num (1997) 127(10):1973–1980.
  • SPRECHER DL, HARRIS BV, GOLDBERG AC et al: Efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high or low fat diets. Ann. Intern. Med. (1993) 119(7 Pt 1):627–628. Psyllium lowers LDL-C.
  • CLARKSON T, ANTHONY M, MORGAN TM: Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens.Clin. Endocrinol Metab. (2001) 86:41–47.
  • ANDERSON JJB, GARNER SC: Editorial: soy phytoestrogens, lipid reductions, and atherosclerosis delay in ovariectomized primates.' Clin. Endocrinol Metab. (2001) 86(1):39–41.
  • SIRTORI SR: Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Sal (2001) 24(9):665–682.
  • ANDERSON JW, JOHNSTONE BM, COOK-NEWELL ME et al.: Meta-analysis of the effects of soy protein intake on serum lipids. N Engl." Med. (1995) 333:276–282.
  • BAUM JA, TENG H, ERDMAN JVV et al: Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am. Clin. Num. (1998) 68(3):545–551.
  • ADAMS MR, GOLDEN DL, ANTHONY MS et al: The inhibitory effect of soy protein isolate on atherosclerosis in mice does not require the presence of LDL receptors or alterations of plasma lipoproteins." Num (2002) 132:43–49.
  • CHORAZY PA, HIMELHOCH S, HOPWOOD NJ et al.: Persistenthypothyroidism in an infant receiving a soyformula: case report and review of the literature. Pediatrics (1995) 96(1 Pt 1):148–150.
  • WILSON GR: Thyroid Disorders. Fam. Pract. (2002) 4(3):667.
  • MARON DJ, LU GP, CAI NS et al: Cholesterol-lowering effect of a theaflavin-enriched green tea extract. Arch. Intern. Med. (2003) 163(12):1448–1453.
  • TAVINTHARAN S, KASHYAP ML: The benefits of niacin in atherosclerosis. Curr. Atheroscler. (2001) 3:74–82.
  • KNOPP RH, GINSBERG J, ALBERS JJ et al.: Contrasting effects of unmodified and time release forms of niacin on lipoproteins in hyperlipidaemic subjects. Clues to mechanism of action of niacin.Metabolism (1985) 34:642–650.
  • MCKENNEY JM, PROCTOR JD, HARRIS S, CHIN CHILI VM: A comparison of the efficacy and toxic effects of sustained release versus immediate release niacin in hypercholesterolemic patients. "AMA (1994) 271(9):672–677.
  • MULLIN GE, GREENSON JK, MITCHELL MC: Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann. Intern. Med. (1989) 111(3):253–255.
  • ETCHASON JA, MILLAR TD, SQUIRES RW et al: Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin. Proc. (1991) 66:23–28.
  • KNOPP RH, ALAGONA P,DAVIDSON M et al: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.Metabolism (1998) 47(9):1097–1104.
  • GOLDBERG A, ALAGONA P, CAPUZZI DM et al: Multiple dose efficacy and safety of an extended release form of niacin in the management of hyperlipidemia. Am. Cardiol (2000) 85(9):1100–1105.
  • MORGAN JM, CAPUZZI DM, GUYTON JR: A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am.j Cardiol (1998) 82(12A): 29U–34U.
  • SOGA T, KAMOHARA M, TAKASAKI J et al.: Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. (2003) 303(1):364–369.
  • YESHURUN D, HAMOOD H, NASCHITZ J: Acipimox (Olbetam) as a secondary hypolidemic agent in combined hypertriglyceridemia and hyperlipidemia. Harefuah (2000) 138(8):650–653; 710.
  • BODEN G: Pathogenesis of Type 2 Diabetes. Endocrinol Metab. Clinics (2001):801–815.
  • CIAMPELLI M, MUZJ G, LEONI F et al: Metabolic and endocrine consequences of acute suppression of FFA's by acipimox in polycystic ovary syndrome. jEndocrinol Metab. (2001) 86(11):5324–5329.
  • HOLUB BJ: Clinical nutrition: 4. Omega-3-fatty acids in cardiovascular care.Can. Med. Assoc. J. (2002) 166(5):608–615.
  • KRIS-ETHERTON PM, HARRIS WS, APPEL LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation (2002) 21:2747–2757.
  • ••A comprehensive discussion of fish oiltherapy and CHD.
  • HARRIS WS: N-3 fatty acids and serum lipoproteins: human studies. Am." Clin. Num. (1997) 65(5 Suppl.):1645S–1654S.
  • GLAUBER H, WALLACE P, GRIVER K, BRECHTEL G: Adverse metabolic effect of omega-3 fatty acids in non-insulin diabetes mellitus. Ann. Intern. Med. (1988) 108:663–668.
  • BAYS HE, DUJOVNE CA: Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Frog. Drug Res. (1994) 43:9–41.
  • VONTORI VM, FARMER A,WOLLAN PC, DINNEEN SF: Fish oil supplementation in Type 2 diabetes: a quantitative systematic review.Diabetes Care (2000) 23(9):1217–1218.
  • FRIEDBERG CE, JANSSEN MJ, HEINE RJ, GROBBEE DE: Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care (1998) 21(0494–500.
  • LEAF A, JORGENSEN MB, JACOBS AK et al.: Do fish oils prevent restenosis after coronary angioplasty? Circulation (1994) 90:2248–2257.
  • ERITSLAND J, ARNESEN H, GRONSETH K et al.: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am. J. Cardiol (1996) 77:31–36.
  • BAYS HE, DUJOVNE CA: Antioxidants in the treatment of atherosclerotic disease.
  • ••Clin. Invest. Arteriosclerosis (1993) 5:30–39.
  • BAYS HE, DUJOVNE CA: The use of antioxidants in clinical practice: past, present and future. Choices M Cardiol (1994) 8:6–8.
  • BURING JE: Vitamin E had no effect on the risk of cardiovascular death, MI, and stroke in patients at high risk for cardiovascular events but without LV dysfunction or HE The Heart Outcomes Prevention Evaluation Study Investigators. Evidence-based Cardiovasc. Med. (2000) 4(4):112A
  • HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet (2002) 360(9326):23–33.
  • BROWN BG, ZHAO XQ, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl. J. Med. (2001) 345:1583–1592.
  • ••A small trial that suggests that CHD canessentially be 'cured' with concomitant use of niacin and statins (without antioxidants).
  • WASSERMAN MA, SUNDELL CL, KUNSCH C et al.: Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Ant. J. Cardiol (2003) 91(3434A–40A.
  • WALLDIUS G, ERIKSON U,OLSSON AG et al: The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PORST). Am.j Cardiol (1994) 74:875–883.
  • JOHANSSON J, OLSSON AG, BERGSTRAND L et al: Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1049–1056.
  • GOUNI-BERHOLD I, BERTHOLD HK: Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering drug. Am. Heart J. (2002) 143(2):356–365.
  • ZIOUZENKOVA 0, PERREY S, MARX N et al: Peroxisome proliferator-activated receptors. Curr. Atheroscler. Rep. (2002) 4(1):59–64.
  • FRUCHART JC, DURIEZ P, STAELS B: Perwdsome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curc Opin. Lipidol (1999) 10(3):245–257.
  • MANNINEN V, KOSKINEN P, MANTTARI M, HUTTUNEN J, CANTER D, FRICK H: Predictive value for coronary heart disease of baseline high-density and low density lipoprotein cholesterol among Frederickson Type IIa subjects in the Helsinki heart study. Am. J. Cardiol (1990) 66:24A–27A.
  • RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl. J. Med. (1999) 341:410–418.
  • BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Intern. Merl (2003) 163:553–564.
  • •A practical review of myopathy and the use of statins.
  • PRUEKSARITANONT T, ZHAO J, MA B et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. Department of drug metabolism. Merck Research Laboratories: West Point, Pennsylvania. J. Pharmacol Exp. Ther. (2002) 301:1042–1051.
  • PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania. Drug Metab. Dispos. (2002) 30:505–512.
  • ELLEN RLB, MCPHERSON: Long term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol (1998) 81:60B–65B.
  • MCKENNEY JM: New cholesterol guidelines, new treatment challenges. Pharmacotherapy (2002) 22(7):853–863.
  • BAYS HE, DUJOVNE CA: Drug interactions of lipid-altering drugs. Drug Sal (1998) 19(5):355–371.
  • BAYS HE, DUJOVNE CA,MCGOVERN ME et al.: Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (The Advicor versus other cholesterol-modulating agents trial evaluation) [ADVOCATE]. Am." CardioL (2003) 91:667–672.
  • ••A direct comparison trial of extended-release niacin/lovastatin versus statin monotherapy on lipoproteins.
  • HEILBRONN LK, NOAKES M, CLIFTON PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arteriosclec Thromb. Vasc. Biol. (2001) 21:968–970.
  • BAYS HE, MCGOVERN ME, SIMMONS PD, KOHLER RM, SUPERKO RH: Niacin extended-release/lovastatin once-daily combination improves low-density and high-density lipoprotein subclass distribution compared to starting doses of atorvastatin and simvastatin. oral contribution July 12th (2003), International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease, New York, USA.
  • BAYS HE, MCGOVERN ME: 'Once-daily niacin extended-release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution compared to atorvastatin and simvastatin. Prey Cardiol (2003) (In Press).
  • •A direct comparison trial of extended-release niacin/lovastatin versus statin monotherapy on lipoprotein particle size and subclass distribution, including a discussion of clinical implications.
  • STEIN EA: Management of dyslipidemia in the high-risk patient. Am. Heart J. (2002) 144(6 Suppl.):S43–S50.
  • BAYS HE: Atherogenic dyslipidaemia in Type 2 diabetes and metabolic syndrome. Br. J. Diabetes Vasc. Dis. (2003) 3\(Issue 5).
  • LUKIC T, PRITCHARD H, WASAN KM: Disodium ascorbyl phytostanyl phosphates, FM-VP4, decreases blood lipids and body weight without observed toxicity. Abstract/Poster, July 1 lth (2003), International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease, New York, USA.
  • HIYOSHI H, YANAGIMACHI M, ITO M et al: Effect of ER-27856, a novel squalene synthase inhibitor on plasma cholesterol in rhesus monkeys : comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. J. Lipid Res. (2000) 41:1136-1144. 1933Expert Op/n. Pharmacother. (2003) 4(11)
  • ROSENBERG SH: Squalene synthase inhibitors. Exp. Opin. Ther. Patents (1998) 8(5):521–530.
  • ROOT C, SMITH CD, SUNDSETH SS et al.: Heal bile acid transporter inhibition, CYP7A1 induction, and antilipemic acion of 264W94.1 Lipid Res. (2002) 43:1320–1330.
  • STEIN EA, RHYNE JM, MCKENNEY J et al.: Intestinal bile acid transport (IBAT) inhibition: results of a 4 week pilot study of 264w94, a novel IBAT inhibitor in hypercholesterolemia. XIV International Symposium on Drugs Affecting Lipid Metabolism New York, NY, USA. September 9–12 (2001) (Abstract).
  • SHAH PK: Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. Rev Cardiovas. Med. (2003) 4(3):136–141.
  • GRAND-PERRET T, BOUILLOT A, PERROT A et al.: SCAP ligands are potent lipid-lowering drugs. Nat. Med. (2001) 7(12):1332–1338.
  • VVETTERAU JR, GREGG RE, HARRITY TW et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751–754.
  • OHASHI K: MTP inhibitors and ACAT inhibitors. An update. Nippon Rinsho. Jap. Clin. Med. (2002) 60(5):975–983.
  • SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor deficient WHHL rabbits by lowering the VLDL secretion. Ear: Pharmacol (2001) 431(1):127–131.
  • MATSUDA K: ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms. Med. Res. Rev. (1994) 14:271–305.
  • LI L, POWNALL HJ: Effects of high-density lipoprotein (2) on cholesterol transport and acyl-coenzyme A: cholesterol acyltransferase activity in P388D1 macrophages. Biochim. Biophys. Acta (2001) 1530:111–122.
  • BOCAN TM, KRAUSE BR,ROSEBURY WS et al.: The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. (2000) 20(1):70–79.
  • HIRAKAWA Y, SHIMOKAWA H: Lipid-lowering drugs. Nippon Yakurigaku Zasshi (2001) 118:389–395.
  • INSULL W, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137–144.
  • TARDIF JC, LESPERANCE GJ, LAMBERT J et al: Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am. Heart J. (2002) 144(4):589–596.
  • •An interesting acknowledgment that many investigational CHD agents may require some type of outcome studies, due to a lack of, or otherwise unimpressive improvement of readily measurable traditional risk factors such as lipid blood levels.
  • BISGAIER CL, ESSENBURG AD, BARBETT BC et al.: A novel compound that elevates high density lipoprotein and activates the perwdsome proliferator activated receptor. Lipid Res. (1998) 39:17–30.
  • BAYS HE, MCKENNEY JM,DUJOVNE CA et al.: Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high density lipoprotein-cholesterol. Am. I Cardiol (2003) 92:538–543.
  • LOCKER PK, JUNGBLUTH GL, FRANCOM SF, HUGHES GS: Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group. Clin. Pharmacol Ther. (1995) 57(1):73–88.
  • VEGA GL, VON BERGMANN K, GRUNDY SM et al.: Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. ./. Intern. Med. (1999) 246(1):1–9.
  • WINKLER K, SCHAEFER JR, KLIMA B et al.: HDL steady state levels are not affected, but HDL apo A-1 turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis (2000) 150(1):113–120.
  • PAPE ME, CRAMER CT, HOPSON KL et al.: Novel pantothenic acid analogues that regulate lipid metabolism through a mechanism involving activation of AMP - activated protein kinase. Second International Symposium on AMP-activated protein kinase. Dundee, Scotland, UK September 12–14 (2002) (Abstract).
  • WINDER WW, HARDIE DG: AMP-activated protein kinase, a metabolicmaster switch: possible roles in Type 2 diabetes mellitus. Am.j Physiol (1999) 277(1 Pt1):El-E10.
  • GADDI A, DESCOVICH GC,NOSEDA G et al: Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia.Atherosclerosis (1984) 50(1):73–83.
  • CORONEL F, TORNERO F, TORRENTE J et al.: Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. Am. Nephrol (1991) 11(1):32–36.
  • OSONO Y, HIROSE N, NAKAJIMA K, HATA Y: The effects of pantethine on fatty liver and fat distribution. I Atheroscler. Thromb. (2000) 7(1):55–58.
  • KAMOHARA ST, MATSUMOTO TJ, SAITO T et al.: Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. (2003) 303(1):364–369.
  • WISE A, FOORD WA, FRASER NJ et al: Molecular identification of high and low affinity receptors for nicotinic acid. Biol. Chem. (2003) 278(11):9869–9874.
  • IIJNARU S, KERO J, SCHAUB A et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. (2003) 9(3):352–355.
  • KUDO MM: Phospholipase A2.Biochem. (Tokyo) (2002) 131(3):285–292.
  • DADA N, KIM NW, WOLFERT RL: Lp-PLA2: an emerging biomarker of coronary heart disease. Exp. Rev. Ma Diagn. (2002) 2(1):17–22.
  • CASLAKE MJ, PACKARD CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curt: Opin. Lipidol. (2003) 14(4):347–352.
  • GOTTO AM: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary heart disease. Am. Heart J. (2002) 144(6):S33–S42.
  • MACPHEE CH; SUCKLING KE: Lipoprotein-associated phospholipase A(2): a target directed at the atheroscerlotic plaque. Expert Opin. Ther. Targets (2002) 6(3):309–314.
  • ISIMIHODIMOS V, KARABINA SA, TAMBAKI AP et al.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase in dyslipidemias of Type IIA and Type IIB. 1934
  • ••AteelOSCIer. The0117. Vase. Biol. (2002) 22(2):306–311.
  • TARDIF JC: Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am. Cardiology (2003) 91(3A):41A–49A.
  • SASAHARA M, RAINES EW, CHAIT A et al.: Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? Clin. Invest. (1994) 94:155–64.
  • SAWAYAMA Y, SHINIZU C, MAEDA N et al.: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia.Am. Coll. Cardiol (2002) 39:610–616.
  • EDITORIAL: You are what you eat. Lancet °flea (2002) 3(9):517.
  • ST-ONGE MP, LAMARCHE B, MAUGERJF, JONES PJ: Consumption of functional oil rich in phytosterols and medium chain triglyceride oil improves plasma lipid profiles. Num. (2003) 133(6):1815–1820.
  • BOURQUE C, ST-ONGE MP, PAPAMANDJARIS AA et al.: Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women. Metabolism (2003) 52(6):771–777.
  • ZUCKERMAN SH, KAUFFMAN RF, EVANS GF: Perwdsome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids (2002) 37(5):487–494.
  • LJUNG B, BAMBBERG K, DAHLLOF B et al.: AZ 242, a novel PPAR alpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucher rats. J. Lipid Res. (2002) 43:1855–1863.
  • RUBIN K, ANDERSON TB, MASIMIREMBWA CM: Tesaglitazar (Galida) does not inhibit the major drug-metabolizing cytochrome p450 enzymes. 63rd Scientific Sessions of the American Diabetes Association, New Orleans, LA, USA June 13–17 (2003) (Abstract).
  • ERICSSON H, BERGSTRAND S, FRYKLUND L et al.: Pharmacokinetics of tesaglitazar (Galida9 in healthy male subjects. Diabetes (2003) 52 (Suppl. 1):P-508 (Abstract).
  • SAMUELSSON S, BERGH S, OHMAN PK, ERICSSON H: Food does not affect the pharmacokinetics of tesaglitazar (Galida9. Diabetes (2003) 52 (Suppl. 1):P-567 (Abstract).
  • DAVIS T: Tesaglitazar (AstraZeneca). IDrugs (2002) 5(9):924–926.
  • CHEN YE, FU M, ZHANG J et al: Perwdsome proliferator-activated receptors and the cardiovascular system. Vit. Horm. (2003) 66:157–188.
  • OLIVER WR, SHENK JL, SNAITH MR et al.: A selective perwdsome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98(9):5306–5311.
  • BALASUBRAMANYAM A: Novel receptors and their functions define pathways of lipid metabolism and mechanisms of atherosclerosis (2003) Medscape Conference Coverage, based on selected sessions at the:ENDO 2003: Endocrine Society 857 Annual Meeting, June 19–22, 2003, Philadelphia, Pennsylvania, USA.
  • •A discussion of nuclear receptors, including the enigmatic PPAR-8.
  • OSBORNE TF: Sterol regulatory element binding proteins (SREBP): key regulators of nutritional homeostasis and insulin action. Biol. Chem. (2000) 275(42):32379–32382.
  • LUND EG, MENKE JG, SPARROW CP: Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Tbrom. Vasc. Biol. (2003) 23:1169–1177.
  • ••LXR agonists have potential benefits, andcurrent problems.
  • SCHULTZ JR, TU H, LUK A et al: Role of LXRs in control of lipogenesis.Genes Dev. (2000) 14(22):2831–2838.
  • EDWARDS PA, KAST HR,ANISFELD AM: BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. Lipid Res. (2002) 43(1):2–12.
  • REPA JJ, BERGE KE, POMAJZL C, RICHARDSON JA, HOBBS H, MANGELSDORF DJ: Regulation of ATP binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. (2002) 277(21):18793–18800.
  • OSTLUND RE: Cholesterol absorption. Curr. Opin. Castroenterol (2002) 18:254–258.
  • REPA JJ, TURLEY SD, LOBACCORO JA et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524.
  • CHAWLA A, REPA JJ, EVANS RM, MANGELSDORF DJ: Nuclear receptors and lipid physiology: Opening the X-files. Science (2001) 294:1866–1870.
  • •A discussion of nuclear receptors and clinical relevance.
  • NIESOR EJ, FLACH, J, LOPES-ANTONI, PEREZ A, BENTZEN CL: the nuclear receptors FXR and LXR alpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr. Pbarma. Des. (2001) 7(4):231–259.
  • SPARROW CP, BAFFIC J, LAM MH et al.: A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. (2002) 277(12):10021–10027.
  • URIZAR NL, LIVERMAN AB,DODDS DT et al.: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 296:1703–1706.
  • SZAPARY PO, WOLFE ML,BLOEDON LT et al.: Guggulipid for the treatment of hypercholesterolemia. A randomized, controlled trial. JAMA (2003) 290:765–772.
  • DAVIES PJ, BERRY SA, SHIPLEY GL et al.: Metabolic effects of rexinoids; tissue specific regulation of lipoprotein lipase activity. Molec. Pliarmacol (2001) 59(2):170–176.
  • SPADY DK, DIETSCHY JM: Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. Lipid Res. (1983) 24:303–315.
  • ••Animal studies of relative cholesterolproduction in various body organs.
  • DIETSCHY JM, TURLEY SD,SPADY DK: Role of liver in themaintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. j. LipidRes. (1993) 34(10):1637–1659.
  • RADER DJ: High-density lipoproteins and atherosclerosis. Am. j Cardiol (2002) 90\(Suppl. 8):62i–70i.
  • JOLLEY CD, WOOLLETT LA, TURLEY SD, DIETSCHY JM: Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or 1935
  • ••apolipoprotein A-1 concentration.J. Lipid Res. (1998) 39:2143–2149.
  • PRICE MJ, SHAH PK: New strategies in managing and preventing atherosclerosis: focus on HDL. Rev Cardiovasc. Medicine. (2002) 3(3):129–136.
  • WATTS GF: The yin and yang of cholesteryl ester transfer protein and atherosclerosis. Clin. Sci. (2002) 103:595–597.
  • ZHONG S, SHARP DS, GROVE JS et al: Increased coronary artery disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. Gin. Invest. (1996) 97:2917–2923.
  • BARTER P: CETP and atherosclerosis. Arteriosc/er. Thromb. Vase. Biol. (2000) 20:2029–2031.
  • BARTER PJ, BREWER B, CHAPMAN MJ et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb. Vasc. Biol. (2003) 23:160.
  • KOTHARI HV, POIRIER KJ, LEE WH, SATOH Y: Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hampsters. Atherosclerosis (1997) 128(1):59–66.
  • •A discussion as to where things stand with regard to the clinical understanding of CETP.
  • WANG J, QIANG H, ZHANG CD, ZHUANG Y: CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease. Gin. Chim. Acta (2002) 322(1-2):85–90.
  • DE GROOTH GJ, KUIVENHOVEN JA, STALENHOEF AF et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor JTT-705, in humans: a randomized Phase II dose-response study. Circulation (2002) 105(18):2159–2165.
  • RITTERSHAUS CW, MILLER DP, THOMAS LJ et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in rabbit model of atherosclerosis. Arterioscler. Thromb. Vase. Biol. (2000) 20:2106–2112.
  • NEWTON RS, KRAUSE BR: HDL therapy for the acute treatment of atherosclerosis. Atherosclerosis Stipp]. (2002) 3(4):31–38.
  • ••`HDL therapy' might soon be one of themore important treatments for atherosclerotic lesions.
  • KRAUSE BR, AUERBACH BJ: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Carr. Opin. Investig. Drugs. (2001) 2(3):375–381.
  • ALAM K, MEIDELL RS, SPADY DK: Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. Biol. Chem. (2001) 276(19):15641–15649.
  • ANANTHARAMAIAH GM, DATTA G, GARBER DW: Toward the design of peptide mimics of antiatherogenic apolipoproteins A-1 and E. Carr. Science (2001) 81(1):53–65.
  • DATTA G, GARBER DW, CHUNG BH et al: Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. Lipid Res. (2001) 42(6):959–966.
  • MARCHIOLI R: Pravastatin reduces mortality in people with and without history of coronary heart disease. Evidence Based Cardiovasc. Medicine. (2002) 6(3):101–102.
  • VERHEUGT FWA, GERSH BJ: Aspirin beyond platelet inhibition. Am. J. Cardiol (2002) 90(1):39–41.
  • FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults. JAMA (2002) 287:356–359.
  • BAYS HE, DUJOVNE CA: Anti-obesity drug development. Exp. Opin. Investig. Drugs (2002) 11(9):1189–1204.
  • ••Anti-obesity drug development involvesunderstanding of past and current research issues and challenges unique to this field, as well as an anticipation of potential future changes in guidelines (based upon historic experience with other metabolic disease treatment guidelines).
  • DAVIDSON M, HAUPTMAN J, DIGIROLOAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat.JAMA (1999) 281:235–242.
  • SJOSTROM L, RISSANEN A,ANDERSEN T et al: Randomized placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet (1998) 352:167–172.
  • MITTENDORFER B, OSTLUND R, PATTERSON BW et al.: Orlistat inhibitsdaily cholesterol absorption. Obes. Res. (2001) 9(10):599–604.
  • HEYMSFIELD SB, SEGAL KR,HAUPTMAN J et al.: Effects of weight loss with orlistat on glucose tolerance and progression to Type 2 diabetes in obese adults. Arch. Intern. Med. (2000) 160(9):1321–1326.
  • ROSSNER S, SJOSTROM L, NOACK R et al: Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res. (2000) 8(1):49–61.
  • LINDGARDE F: The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. I Intern. Med. (2000) 248(3):245–254.
  • WIRTH A, KRAUSE J: Long-term weight loss with sibutramine. JAMA (2001) 286:1331–1339.
  • JAMES WP, ASTRUP A, FINER N et al.: Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet (2000) 356:2119–2125.
  • LEAN MEJ: Sibutramine - a review of clinical efficacy. Int. J. Obes. (1997) 21 (Suppl. 1):530–536.
  • FUJIOKA K, SEATON TB, ROWE E et al.: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabet. Obes. Metab. (2000) 2(3):175–187.
  • FINER N, BLOOM SR, FROST GS et al: Sibutramine is effective for weight loss and diabetic control in obesity with Type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabet. Obes. Metab. (2000) 2(2):105–112.
  • BAYS HE, DUJOVNE CA: Pharmacotherapy of obesity. Currently marketed and upcoming agents. Am. J. Cardiovasc. Drugs. (2002) 2(4):245–253.
  • AMARENCO P: Hypercholesterolemia, lipid-lowering, and the risk for brain infarction. Neurology (2001) 57(5 Suppl.):S35–S44.
  • ••Hypercholesterolaemia may be more of arisk factor for stroke than what has been suggested by clinical trials, with implications regarding the need of treatment of dyslipidaemia to prevent 'brain infarction'.
  • DANESH J, COLLINS R, PETO R: Lipoprotein (a) and coronary heart disease.
  • ••Meta-analysis of prospective studies. Evidenced based Cardiovasc. Med. (2001) 5(2):63–64.
  • WIESBAUER F, MILES JS: C-reactive protein screening for cardiovascular disease. Editor's correspondence. Arch. Intern. Med. (2003) 163:242.
  • MIKE M: Panel endorses limited role for CRP test. "AMA (2003) 289:973–974.
  • ••Measurement of CRP may provide usefulprognostic information for some patients.
  • MEZZANO D, LEIGHTON F, MARTINEZ C et al.: Complementary effects of Mediterranean diet and moderate red wine intake on haemostatic cardiovascular risk factors. Ear: j Clin. Num. (2001) 55:444–451.
  • MORIARITY PM, GIBSON CA, SHIH J, MATIAS MS: C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis (2001) 158:495–498.
  • JIALAL I, STEIN D, BALIS D, GRUNDY SM, ADAMS-HUET B, DEVARAJ S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation (2001) 103:1933–1935.
  • MACMAHON M, KIRKPATRICK C, CUMMINGS CE et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Num. Metab. Cardiovasc.Dis. (2000) 10:195–203.
  • MUSIAL J, UNDAS A, GAJEWSKI P, JANKOWSKI M, SYDOR W, SZCZEKLIK A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol. (2001) 77:247–253.
  • STRANDBERG TE, VANHANEN H, TIKKANEN MJ: Associations between change in C-reactive protein and serum lipids during statin treatment. Ann. Med. (2000) 32:579–583.
  • BAYS HE, STEIN EA, SHAH AK, MACCUBBIN DL, MITCHEL YB, MERCURI M: Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am. I Cardiol. (2002) 90(9):942–946.zoz. RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNWALD E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. TheCholesterol And Recurrent Events (CARE) Investigators. Circulation (1999) 100:230–235.
  • DOWNS JR, CLEARFIELD M, VVEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. The AFCAPS/TexCAPS Research Group. "AMA (1998) 279:1615–1622.
  • RIDKER PM, RIFAI N, CLEARFIELD N et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. (2001) 344:1959–1965.
  • RIDKER PM, RIFAI N,LOWENTHAL SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation (2001) 103:1191–1193.
  • STAELS B, KOENIG W, HABIB A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARy activators. Nature (1998) 393:790–793.
  • DE-MAAT MP, KNIPSCHEER HC, KASTELEIN JJ, KLUFT C: Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb. Haemost. (1997) 77:75–79.
  • KNIPSCHEER HC, DE VALOIS JC, VAN DEN ENDE B, WOUTER TEN CATE J, KASTELEIN JJP: Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidemia. Atherosclerosis (1996) 124:S75–S81.
  • KASHYAP ML, MCGOVERN ME, BERRA K et al.: Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol (2002) 89(6):672–678.
  • GRUNDY SM, VEGA GL,MCGOVERN ME et al.: Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes. Arch. Intern. Med. (2002) 162:1568–1576.
  • IKONOMIDIS I, ANDREOTTI F, ECONOMOU E, STEFANIDIS C, TOUTOUZAS P, NIHOYANNOPOULOS P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation (1999) 100:793-798 (Abstract).
  • SOLHEIM S, SELJEFLOT I, HURLEN M, ARNESEN H: The influence of aspirin on inflammatory markers in patients after myocardial infarction. Ear: Heart J. (2001) 22(Suppl.):241 (Abstract).
  • CHUNG HS, BECKER DM, YANEK LR et al.: Daily low dose aspirin therapy is associated with lower levels of inflammatory biomarkers in a high-risk population without coronary disease. Circulation (2002) 106:3585 (Abstract).
  • FELDMAN M, JIALAL I, DEVARAJ S, CRYER B: Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll Cardiol. (2001) 37:2036–2041.
  • GIUGLIANO GR, GIUGLIANO RP, GIBSON CM, KUNTZ RE: Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am. J. Cardiol. (2003) 91(9):1055–1059.
  • VILLEPONTEAU B, COCKRELL R, FENG J: Nutraceutical interventions may delay aging and the age-related diseases. Exp. Cerontol (2000) 35(9-10):1405–1417.
  • FERRARI CK, TORRES EA: Biochemical pharmacology of functional foods and prevention of chronic diseases of aging. Biomed. Pharmacother. (2003) 57(5-6):251–260.
  • HEYLAND DK: In search of the magic nutraceutical: problems with current approaches. J. Num. (2001) 131(9 Suppl.):2591S–2595S.
  • •Current data concerning the benefits of nutraceuticals may need confirmation.
  • BAYS HE, DUJOVNE CA: Lipid-altering drugs in development. Drugs RD (1999) 1(6):463–469.
  • THOMPSON PD, CLARKSON P, KARAS RH: Statin-associated myopathy. "AMA (2003) 289:1681–1690.
  • BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163:553–564.
  • DEAN M, HAMON Y, CHIMINI G: The human ATP-binding cassette (ABC) transporter superfamily. Lipid Res. (2001) 42(7):1007–1017.
  • DUJOVNE CA, ZAVORALJH, ROWE E, MENDEL CM: Effects of sibutramine on body weight and serum lipids. Am. Heart J. (2001) 142(3):489–497.
  • BUSE JB: Lipid changes associated with diabetes therapy. Practical Diabetology (2003):24–29.
  • MCKENNEY JM, MCCORMICK LS, SCHAEFER EJ et al.: Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am. J. Cardiol (2001) 88:270–274.

Websites

  • http://www.americanheart.orgHeart Disease and Stroke Statistics — 2003 update. American Heart Association Website — Publicatons and Resources, Statistics. Accessed September 2003.
  • http://www.lassa.org.za/dalm2001.htm MTP INHIBITORS:Implitapide Drugs Affecting Lipid Metabolism XIV Meeting, Manhatten, New York, USA, 9 — 12 September 2001,Accessed September 2003.
  • http://www.rotman.utoronto.ca/ —norli/tc h/mgt431-2002/ Announcement_Pfizer_SVP.doc CP-529,414 also lowers LDL-C Pfizer, Inc. Accessed September 2003.
  • http://www.who.int/nut/obs.htm WHO: Controlling the global obesity epidemic (1 May 2003)Accessed September 2003.
  • http://www.who.int/health_topics/diabetes_ mellitus/en/WHO: Diabetes Mellitus Fact Sheets Revised April 192002Accessed September 2003.
  • http://www.astrazeneca-us.com/ news/article.asp?file= 192003031801.htm AstraZeneca announces initiation of largest long-term study to determine the effects of Crestor® and C-reactive protein on cardiovascular disease risk reduction. AstraZeneca US news roomAccessed September 2003.
  • http://www.lipidsonline.org/slides/slideOl.cfm?t k=18BARTER P: Browsing talk: role of lipoproteins in inflammation. http://www.lipidsonline.orgAcessed October 2003. (Derived from: DOI H, KUGIYAMA K, OKA H, SUGIYAMA S, OGATA N, KOIDE SI, NAKAMURA SI, YASUE H: Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation (2000) 102:670-676.)Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.